View/ Open
cancers-09-00056.pdf (358.6Kb)
Download
Publication date
26/05/2017Rights
© 2017 The Authors. This is an open access article distributed under the Creative Commons CC-BY license (https://creativecommons.org/licenses/by/4.0/) which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.Peer-Reviewed
YesOpen Access status
openAccessAccepted for publication
23/05/2017
Metadata
Show full item recordAbstract
Alterations in integrin expression and function promote tumour growth, invasion, metastasis and neoangiogenesis. Head and neck cancers are highly vascular tumours with a tendency to metastasise. They express a wide range of integrin receptors. Expression of the αv and β1 subunits has been explored relatively extensively and linked to tumour progression and metastasis. Individual receptors αvβ3 and αvβ5 have proved popular targets for diagnostic and therapeutic agents but lesser studied receptors, such as αvβ6, αvβ8, and β1 subfamily members, also show promise. This review presents the current knowledge of integrin expression and function in squamous cell carcinoma of the head and neck (HNSCC), with a particular focus on the RGD-binding integrins, in order to highlight the potential of integrins as targets for personalised tumour specific identification and therapy.Version
Published versionCitation
Ahmedah HT, Patterson LH, Shnyder SD et al (2017) RGD-Binding Integrins in Head and Neck Cancers. Cancers. 9(6). 56.Link to Version of Record
https://doi.org/10.3390/cancers9060056Type
Articleae974a485f413a2113503eed53cd6c53
https://doi.org/10.3390/cancers9060056